Thomas O Carpenter
Overview
Explore the profile of Thomas O Carpenter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
3510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ali D, Carpenter T, Imel E, Ward L, Appelman-Dijkstra N, Chaussain C, et al.
J Clin Endocrinol Metab
. 2025 Feb;
PMID: 39960858
Background: An International Working Group (IWG) developed new guidelines on the diagnosis, evaluation, management, and monitoring of X-linked hypophosphatemia (XLH) in children. Over the past 5 years, important advances have...
2.
Ali D, Mirza R, Hussein S, Alsarraf F, Alexander R, Abu Alrob H, et al.
J Clin Endocrinol Metab
. 2025 Jan;
PMID: 39787354
Objective: To examine the evidence addressing the management of X-linked hypophosphatemia (XLH) in children to inform treatment recommendations. Methods: We searched Embase, MEDLINE, Web of Science, and Cochrane Central up...
3.
Ali D, Mirza R, Alsarraf F, Hussein S, Abu Alrob H, Appelman-Dijkstra N, et al.
J Clin Endocrinol Metab
. 2024 Dec;
PMID: 39715351
Objective: To examine the highest certainty evidence addressing the management of X-linked hypophosphatemia (XLH) in adults to inform treatment recommendations. Methods: We searched Embase, MEDLINE, Web of Science, and Cochrane...
4.
Reichenberger E, OBrien K, Hatori A, Carpenter T, van de Wetering K, Flaman L, et al.
JBMR Plus
. 2024 Aug;
8(9):ziae103.
PMID: 39165910
Craniometaphyseal dysplasia (CMD) is a rare genetic bone disorder, characterized by progressive thickening of craniofacial bones and flared metaphyses of long bones. Craniofacial hyperostosis leads to the obstruction of neural...
5.
Goldsweig B, Turk Yilmaz R, Ravindranath Waikar A, Brownstein C, Carpenter T
J Bone Miner Res
. 2024 Aug;
39(10):1406-1411.
PMID: 39163488
Familial hypocalciuric hypercalcemia (FHH) is typically a benign condition characterized by elevated serum calcium, low urinary calcium excretion, and non-suppressed circulating levels of parathyroid hormone (PTH), usually requiring no intervention....
6.
de Beur S, Dahir K, Imel E, Zanchetta M, Williams A, Li Z, et al.
J Clin Endocrinol Metab
. 2024 Jun;
110(1):102-113.
PMID: 38913723
Context: Tumor-induced osteomalacia (TIO) is an ultra-rare, paraneoplastic syndrome caused by tumors that secrete fibroblast growth factor 23 (FGF23). Initial signs and musculoskeletal symptoms can be nonspecific and unrecognized, leading...
7.
Ansh A, Stabach P, Ciccone C, Cao W, De La Cruz E, Sabbagh Y, et al.
Bone
. 2024 May;
186:117136.
PMID: 38806089
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) codes for a type 2 transmembrane glycoprotein which hydrolyzes extracellular phosphoanhydrides into bio-active molecules that regulate, inter alia, ectopic mineralization, bone formation, vascular endothelial proliferation, and...
8.
Kayser M, Jain P, Bale A, Carpenter T
JCEM Case Rep
. 2023 Nov;
1(5):luad082.
PMID: 37908207
X-linked hypophosphatemia (XLH), the most common form of hereditary rickets, is due to inactivation of resulting in increased circulating fibroblast growth factor 23. Consequent renal phosphate loss leads to hypophosphatemia,...
9.
Ferreira C, Carpenter T, Braddock D
Annu Rev Pathol
. 2023 Oct;
19:507-540.
PMID: 37871131
The enzyme ectonucleotide pyrophosphatase/phosphodiesterase 1 () codes for a type 2 transmembrane glycoprotein that hydrolyzes extracellular ATP to generate pyrophosphate (PP) and adenosine monophosphate, thereby contributing to downstream purinergic signaling...
10.
Simpson C, Santoro A, Carpenter T, Deng Y, Parziale S, Insogna K
J Endocr Soc
. 2023 Oct;
7(11):bvad116.
PMID: 37860221
Individuals with X-linked hypophosphatemia (XLH) are at greater risk for being overweight or obese. Whether there are underlying metabolic abnormalities that put patients with XLH at greater risk for excessive...